Business Wire

CA-ALKIRA/CHECK-POINT

29.9.2021 16:12:04 CEST | Business Wire | Press release

Share
Alkira and Check Point Software Technologies Collaborate to Bring Enterprise-Class Security to Cloud Workloads

Cloud networking pioneer Alkira® and Check Point Software Technologies (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced a technology alliance to provide Check Point Software’s CloudGuard firewalls in Alkira’s Cloud Network infrastructure as-a-Service (CNaaS). This comes as organizations deploying application workloads to the cloud are struggling with the complexity of implementing consistent enterprise-wide security controls spanning cloud, multi-cloud and on-premises environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005357/en/

The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads enabling customers to deploy the same robust security in the cloud that they are used to with on-premises systems. Alkira brings a high-performance cloud network-as-a-service with global virtual infrastructure, advanced routing, intelligent service insertion and dynamic auto-scale, simplifying set-up and day 2 operations for enterprise cloud networking and security deployments.

Atif Khan, CTO and Founder of Alkira, said:
“Alkira and Check Point simplify security deployments and make it easier for enterprise customers to apply a single security posture across the entire enterprise network spanning cloud, multi-cloud and existing data center or colocation facilities. Delivering the Alkira virtual network infrastructure and Check Point security management tools as a service allows enterprises to avoid the costs and complexity of DIY solutions, and provides guaranteed performance and scalability.”

TJ Gonen, Head of Cloud Security at Check Point added :
“The combination of Check Point CloudGuard and Alkira simplifies the process of provisioning and ongoing management in the cloud networking environment which is a big win for enterprise customers. The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads, across public, hybrid and multi-cloud environments, enabling customers to benefit from a single unified security platform.”

Alkira Cloud Services Exchange® (CSX) fully automates the provisioning, licensing, service insertion, scaling and health monitoring of CloudGuard network security gateways. Alkira seamlessly inserts the CloudGuard gateways at any point in the Alkira global cloud backbone, providing stateful security controls for any on-premises, cloud, and Internet application traffic. Alkira allows customers to decouple CloudGuard from the specific cloud providers, thus providing a more efficient multi-cloud security architecture.

Cloud environments offer global presence and vast compute resources but lack the necessary routing, policy and operational controls enterprises require for a streamlined cloud firewall deployment. Even in a single cloud environment, do-it-yourself solutions result in a complex sprawl of virtual machine instances and traffic management scenarios. They also tend to make inefficient use of resources. All these problems are made worse in multi-cloud environments.

Check Point CloudGuard can be rapidly provisioned into one or multiple globally distributed Alkira Cloud Exchange Points (CXP) to provide security policy enforcement for application traffic between any set of endpoints connected to the Alkira global cloud backbone. Once CloudGuard has been provisioned within an Alkira CXP it can provide:

  • Security policy to and between public clouds
  • Cloud hosted, stateful firewall services for branches and data centers
  • Regionalized Internet breakouts for secure SaaS application access
  • Cloud DMZ environment for Internet facing applications
  • Shared cloud application services for partners and M&As

Alkira’s visual policy manager simplifies policy configuration, scoping and inspection, and streamlines auditing for assurance and compliance purposes. Alkira’s intent-based approach selectively routes traffic to firewalls according to need, improving efficiency of firewall utilization and optimizing network performance. Customers have a choice of bring-your-own license (BYOL) or pay-as-you-go (PAYG) licensing models.

Check Point offers a multilevel security architecture that defends enterprises’ cloud, network and mobile device-held information, and a comprehensive and intuitive one-point-of-control security management system.

CloudGuard is available in the Alkira network services marketplace.

For more information:

About Alkira

Alkira® delivers Cloud Networking as-a-Service (CNaaS) and developed the first Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and security services, and end-to-end visibility and governance. Alkira Cloud Services Exchange® (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira CSX is available on the AWS and Azure Marketplaces. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP and founding team member at Viptela. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet

Alkira® , Alkira Cloud Services Exchange® and Alkira Cloud Exchange Point® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/alkirainc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye